Medpace, Inc.
Work Here?
About Medpace, Inc.
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Irving, Texas
Founded
1992
Overview
Simplify's Take
What believers are saying
- Significant revenue growth in Q4 2023 indicates strong market demand and effective strategies.
- Recent investments by financial institutions reflect confidence in Medpace's growth potential.
- Expansion of medical leadership team suggests increased focus on clinical research and development.
What critics are saying
- Increased competition from Lantheus and others may pressure Medpace's market share.
- New Cincinnati office construction could lead to higher operational costs and project delays.
- Decreased net income margin in 2023 indicates challenges in maintaining profitability.
What makes Medpace, Inc. unique
- Medpace's expansion in infectious diseases and vaccines shows strategic focus on high-demand sectors.
- New leadership in respiratory and women's health enhances Medpace's expertise and service offerings.
- Commitment to infrastructure growth with new Cincinnati office supports future operational efficiency.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$924.3M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Flexible Work Hours
Unlimited Paid Time Off
Competitive Compensation and Benefits Package
Employee Health and Wellness Initiatives
Hybrid Work Options
Structured Career Paths with Opportunities for Professional Growth
Company News
Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.
STOCKHOLM, Aug. 15, 2024 /PRNewswire/ - Skanska has signed a contract with Medpace, a clinical research company, for the construction of a new office building in Cincinnati, Ohio, USA.
First National Bank of Hutchinson invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP).
Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%.Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x.Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter of 2023 and 2022, respectively.EBITDA was $95.8 million for the fourth quarter of 2023, an increase of 19.2% from EBITDA of $80.4 million for the comparable prior-year period, resulting in an EBITDA margin of 19.2%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Results
Hussman Strategic Advisors Inc. invests $1.02 million in Medpace Holdings, Inc. (NASDAQ:MEDP).
Medpace, Inc. is Hiring for 471 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Medpace, Inc.
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Irving, Texas
Founded
1992
Medpace, Inc. is Hiring for 471 Jobs on Simplify!
Find jobs on Simplify and start your career today